SPOTLIGHT: CytRx stock plunges on trial halt

Shares of CytRx plunged on the news that the FDA had halted a mid-stage trial for a drug to treat Lou Gehrig's disease. Regulators want to take some time to analyze results from animal studies of arimoclomol. CytRx stock was down 38 percent on a rough day. Release | Report

Suggested Articles

Zydus Cadila has completed a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 .

A month after scoring $1.6 billion from the U.S. government, Novavax is posting the first human data from its COVID-19 vaccine.

CureVac named a permanent CEO, Franz-Werner Haas, and signed Novartis alum, Igor Splawski, Ph.D. as its new top scientist.